5-Amino-1MQ

5-Amino-1MQ is a synthetic, small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). NNMT is primarily responsible for methylating nicotinamide (a form of vitamin B3), a process that depletes cellular levels of NAD+ (nicotinamide adenine dinucleotide). By selectively blocking NNMT, 5-Amino-1MQ is designed to potently elevate intracellular NAD+ levels, particularly in metabolically active tissues like adipose tissue, liver, and muscle, thereby resetting cellular energy metabolism.

Mechanisms of action:

5-Amino-1MQ exerts its effects by inhibiting a single key enzyme, which triggers a cascade of metabolic improvements centered on enhanced NAD+ bioavailability:

• NNMT enzyme inhibition: The compound binds to and potently inhibits nicotinamide N-methyltransferase (NNMT). This enzyme normally converts nicotinamide (NAM) into methylnicotinamide (MeNAM), effectively removing NAM from the NAD+ salvage pathway. Inhibition prevents this waste, making more NAM available for NAD+ synthesis.
• Elevation of cellular NAD+ levels: With NNMT blocked, the NAD+ salvage pathway operates at peak efficiency, leading to a significant increase in intracellular NAD+ concentrations. NAD+ is an essential coenzyme for hundreds of metabolic reactions and is a required substrate for sirtuins, a family of longevity-associated deacetylase enzymes.
• Sirtuin activation and epigenetic regulation: The increased NAD+ availability activates sirtuins (SIRT1, SIRT3). Activated sirtuins deacetylate histones and transcription factors, leading to upregulated mitochondrial biogenesis, enhanced fat oxidation, improved insulin sensitivity, and reduced inflammation.
• Systemic metabolic and energetic benefits: This NAD+-Sirtuin axis drives a fundamental shift in cellular energy management:
• Enhances mitochondrial function: Increased SIRT1 and SIRT3 activity stimulates the creation of new mitochondria and improves the efficiency of existing ones, boosting cellular ATP production.
• Promotes a healthy metabolic phenotype in adipose tissue: In fat cells, NNMT inhibition and subsequent sirtuin activation increase energy expenditure, promote “browning” of white adipose tissue (increasing calorie-burning beige fat), and reduce fat cell size and inflammation.
• Improves glucose homeostasis and insulin sensitivity: By improving mitochondrial function and reducing inflammation in liver and muscle, the peptide helps restore normal glucose uptake and utilization.

Research and potential applications:
5-Amino-1MQ’s targeted action on the NNMT-NAD+ axis positions it as a potential metabolic disease modifier, addressing the core energetic deficit common to obesity, diabetes, and aging.

• Metabolic syndrome and type 2 diabetes: By directly improving insulin sensitivity, reducing adiposity, and lowering inflammation, it is positioned to treat the root metabolic dysfunctions of these conditions.
• Obesity and body composition management: Its ability to increase energy expenditure in fat tissue and promote a more metabolically active adipocyte phenotype makes it a candidate for sustainable weight loss and fat reduction.
• Non-alcoholic fatty liver disease (NAFLD/MASLD): The improvement in hepatic NAD+ levels and mitochondrial function directly targets the accumulation of fat and inflammation in the liver.
• Healthy aging and longevity support: By elevating NAD+ and activating sirtuins, two central pillars of the aging biology, it is relevant for interventions aimed at extending healthspan and combating age-related metabolic decline.

In essence, 5-Amino-1MQ functions as a metabolic liberator, designed to remove a specific enzymatic brake (NNMT) on the body’s energy currency (NAD+), thereby unlocking enhanced mitochondrial efficiency, fat burning, and youthful metabolic regulation across key organs.